Company to view next
Generic selectors
Exact matches only
Search in title
Search in content

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

10

Address:

Akari Therapeutics, Plc 75/76 Wimpole Street London W1G 9RT United Kingdom

Website:

http://www.akaritx.com

Phone:

44 20 8004 0270

Leave a comment

Your email address will not be published. Required fields are marked *